Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001999 | 1.00 | FAAH (0.52) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL4076093 | 0.98 | FAAH (0.56) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL23520532 | 0.98 | FAAH (0.56) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL13864077 | 0.98 | FAAH (0.56) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL10002197 | 0.92 | EPHX1 (0.43) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL5469606 | 0.87 | CA2 (0.37) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL5457097 | 0.84 | CA2 (0.37) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL17092516 | 0.84 | CA2 (0.37) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL6895720 | 0.81 | EPHX1 (0.37) | FAAHCA2CES1CES2EPHX1 | |
| SCHEMBL21414876 | 0.81 | CA1 (0.37) | CA2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527158-B | Method for constructing fluorine-containing methyl sulfone compound by multi-component coupling | 华东师范大学 | 2023-02-07 | — | — | CN | disclosed |
| CN-113527158-A | Method for constructing fluorine-containing methyl sulfone compound by multi-component coupling | 华东师范大学 | 2021-10-22 | — | — | CN | disclosed |
| US-11022884-B2 | Silicon-containing resist underlayer film-forming composition having halogenated sulfonylalkyl group | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-20170296585-A1 | IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9751049-B2 | Compositions and methods of cleaning polyvinyl pyrrolidone-based hemodialysis filtration membrane assemblies | NOVAFLUX INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170168397-A1 | SILICON-CONTAINING RESIST UNDERLAYER FILM-FORMING COMPOSITION HAVING HALOGENATED SULFONYLALKYL GROUP | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-9063416-B2 | Resist composition, method of forming resist pattern and compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20130157197-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| EP-2128980-A2 | Acoustic wave device and high-frequency filter using the same | Hitachi Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008060999-A1 | PIPERIDINYL ARYLSULFONE DERIVATIVES AS MODULATORS OF SECRETED FRIZZLED RELATED PROTEIN-1 | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1212296-B9 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1212296-B1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | SOUTHERN CALIFORNIA, UNIVERSITY OF | 2004-11-18 | — | — | US | disclosed |
| WO-2004063129-A2 | METHODS FOR NUCLEOPHILIC FLUOROMETHYLATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040138255-A1 | Phosphate mimics and methods of treatment using phosphatease inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | disclosed |
| US-6596772-B1 | Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are | SUGEN, INC. | 2003-07-22 | — | — | US | disclosed |
| EP-1212296-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6403802-B1 | MIXING IN LIQUID MEDIUM STRONG BASE, ARYL HALIDE OR ARYL PSEUDOHALIDE, PRIMARY AND/OR SECONDARY AMINE, NICKEL, PALLADIUM OR PLATINUM COMPOUND, N-HETEROCYCLIC CARBENE SUCH AS IMIDAZOLINE-2-YLIDENE, BIS(IMIDAZOLINE-2-YLIDENE) OR SALTS | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001066248-A2 | C-C AND C-N COUPLING CATALYST COMPRISING TRANSITION METAL AND CARBENE | UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001016097-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | PHF2, HAO2, GSTM2 | FAAH 1042/4885CA2 204/4885CES1 662/4885 |
| US-20040138255-A1 | Phosphate mimics and methods of treatment using phosphatease inhibitors | PPP4C, PTPRO, PTPRS | FAAH 4379/4885CA2 283/4885CES1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.